Infectious Diseases – Products

Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.

With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd.

First commercial source of on-demand GMP CD34+ hematopoietic stem cells for clinical manufacturing in the industry. OrganaBio leveraging years of in-house tissue sourcing and cell isolation experience to produce high-quality GMP-compliant cells.

Revolutionary genomic research applied an innovative use of multiomics and biomimetic digital twins to unveil new DNA variants associated with the development of endometrial related disorders.

Invitrogen™ GeneArt™ services provide gene synthesis support from DNA design to protein production.

ProBioGen, is pleased to announce the execution of services and license agreements with MAPP BIOPHARMACEUTICAL, INC. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection.

This application note explores a qualified method designed to produce high-quality sequencing libraries, using a hybrid-capture resequencing approach to increase throughput and reproducibility while minimizing the potential for human error.

Ensure the highest standard of patient safety with the Microsart® ATMP Sterile Release Kit, the definitive solution for rapid detection of bacterial and fungal contamination in cell therapy products. Our kit combines the precision of Microsart® ATMP Bacteria and Microsart® ATMP Fungi tests, utilizing the trusted real-time PCR method to deliver accurate results within just 3 hours.

With the Microsart® ATMP Sterile Release Kit, you can confidently release contamination-free cell therapy products, significantly reducing the reliance on prophylactic antibiotics and safeguarding patient health. Our unique kit stands alone in the market, offering an unmatched level of testing that no other product can provide.

Study demonstrates proof-of-concept and strong safety profile of Aurase Wound Gel in patients suffering from chronic wounds.

Diasorin announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company’s new LIAISON PLEX^® platform as well as its first panel of tests, the LIAISON PLEX^® Respiratory Flex Assay.